Rhythm Biosciences Limited · ASX:RHY
Rhythm Biosciences — Shareholder Meeting (November 2024)
22 slides from Rhythm Biosciences's shareholder meeting presentation, Nov 20, 2024
Slide 1: AGM Chairman's Address & Post Meeting Shareholder Presentation
ASX Announcement 20 November 2024 AGM Chairman’s Address & Post Meeting Shareholder Presentation Transformative, predictive cancer diagnostics technology company, Rhythm Biosciences Ltd (ASX: RHY) (Rhythm or the Company), is pleased to provide a written version of the Non-Executive Chairman’s Addres
Slide 2: Chairman's Address (continued)
I would also like to thank Mr Tony Batsakis from our audit partner, BDO for attending today to answer any shareholder queries in relation to the audit or the audit report. We also have Mr Andrew Gaffney from K&L Gates, whose office we are utilising today and Mr Michael Port and Mr James Barci from o
Slide 3: About Rhythm Biosciences
- ENDS - Authorised for release by the Board. For further information contact us via investors@rhythmbio.com: Dr David Atkins Ms Andrea Steele Chief Executive Officer Joint Company Secretary & General Counsel About Rhythm Biosciences Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, med
Slide 4: Post-AGM Investor Presentation
Post-AGM Investor Presentation 20 NOVEMBER 2024
Slide 5: Disclaimer
Disclaimer This presentation has been prepared by Rhythm Biosciences Limited (Rhythm) and is provided for general information purposes only. No party other than Rhythm has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or undert
Slide 6: Executive Summary
Executive Summary • Rhythm Biosciences is developing and commercialising novel clinical cancer diagnostics. Overview • ColoSTAT® is a 2nd generation multiplex assay designed to detect bowel cancer in a patient blood sample that is in the final stages of development ahead of commercialisation in 2025
Slide 7: Why Rhythm Biosciences?
Why Rhythm Biosciences? Rhythm Biosciences is committed to saving lives through early detection of cancers using simple and accurate diagnostic technology. Developing novel screening solutions for specific cancers via patient friendly blood tests is our primary focus. Patent protected; fully charact
Slide 8: Corporate overview
Corporate overview CORPORATE SNAPSHOT SHARE PRICE CHART - ASX:RHY ASX Code RHY 2 1.8 Share Price (at 15 Nov 2024) $0.115 1.6 1.4 Shares on Issue 248.5M 1.2 1 Unlisted Options 21M 0.8 0.6 Market Capitalisation $28.58M 0.4 Top 20 Shareholders 42% 0.2 0 09 Nov 09 Arp 09 Sep 09 Feb 09 Jul 09 Dec 09 May
Slide 9: Our Clinical Advisory Board
Our Clinical Advisory Board Sally Prof Prof Benton Jon Emery Finlay Macrae Consultant Clinical Biochemist and Herman Professor of Primary Care Cancer Head of Colorectal Medicine and Genetics at Clinical Lead for Clinical and Specialist Research at the University of Melbourne, and The Royal Melbourne
Slide 10: When diagnosed early, CRC can be successfully treated
When diagnosed early, CRC can be successfully treated Disease stage at diagnosis is the key predictor of survival in patients with CRC Missed detection of early-stage CRC results in poor survival rates Diagnoses at Stage I or II only represent Stage at less than half of all CRCs diagnosed in: diagno
Slide 11: Participation in CRC screening programs needs improvement
Participation in CRC screening programs needs improvement Based on current participation rates to CRC screening, Addressable 33–56% of the eligible population across Population Addressable Australia, Europe, UK and US remains unscreened. 45.1 million†† Population Participation rates in CRC screening
Slide 12: There are >250 million people who could benefit from an improved blood test
There are >250 million people who could benefit from an improved blood test UNSCREENED % OF TOTAL SCREENING POPULATION/ INCIDENCE OF CRC ADDRESSABLE MARKET POPULATION AGE – SCREENING POPULATION SCREENING METHOD PARTICIPATION RATE OPPORTUNITY (cases per year) MARKETS Europe (EU-27) 746.4 m 231.0 m (5
Slide 13: First major clinical performance evaluation
First major clinical performance evaluation Prospective, multi-centre study to evaluate the clinical performance of the first generation ColoSTAT® for the detection of CRC¹ STUDY DESIGN PRIMARY ENDPOINT Blood-based assay The primary endpoint was to evaluate ColoSTAT® performance compared to N= 989 p
Slide 14: Second generation ColoSTAT clinical assay
Second generation ColoSTAT® clinical assay Standardised, simpler, faster turnaround time and lower cost Multiplex Planar – Five Plates to a Single Plate Based ELISA (Five reagents to a single kit) Reduced Cost Materials, Packaging and Transport Reduced Chance of Human Error Embraces Increased Automa
Slide 15: General population screening for CRC remains the ultimate goal
General population screening for CRC remains the ultimate goal Targeting “intermediate” applications represent valuable intermediate steps towards the end goal TECHNICAL COMPLEXITY ‘Intermediate’ Means • Higher prevalence of cancer. SCREENING • Greater flexibility CONFIRMATION / TRIAGE around curren
Slide 16: Upcoming value inflection points
Upcoming value inflection points ESTIMATED DELIVERY ITEM DESCRIPTION DATE Alpha Assay Ready Arrival of Alpha kits for testing Beta Release Candidate Beta Kits ready for verification 2H CY24 Kit Validation Ready Kit Verification completion, Production Kits Ready. 1H CY25 Commercialisation Partner’s I
Slide 17: Platform technology expansion pipeline
Platform technology expansion pipeline Biomarker analysis complete in significant patient sample study for 3 major cancers STAGE 1 STAGE 2 STAGE 3 STAGE 4 STAGE 5 INITIATION FORMULATION DESIGN & FINAL Product Launch Opportunity and Concept and DEVELOPMENT VALIDATION & Post-Launch Risk Analysis Feasi
Slide 18: Placement Issue Offer
Placement Issue Offer Key details of the Offer Placement Offer New Share Issue, plus • 2 New Options (ASX: RHYO) for every 3 New Shares subscribed under the Offer; and • Additional, new ASX Listed Options to purchase a Share with an exercise price of $0.20 and an Expiry Date of 31 March 2026 (subjec
Slide 19: Use of Funds
Use of Funds Use of funds Progress Product Development – 2nd Generation ColoSTAT®. Complete development and production of ColoSTAT ® Multiplex test kits in conjunction with Up to $0.70m product development partner in North America. Clinical Validation Program and preparation regulatory approvals. Cl
Slide 20: Indicative Timetable of the Offer
Indicative Timetable of the Offer Event Prospectus Date Tuesday, 19 November 2024 Closing Date Tuesday, 19 November 2024 Issue of the New Shares Wednesday, 27 November 2024 Trading (T+2) of New Shares expected to commence Friday, 29 November 2024 Issue of the New Options (subject to Shareholder Janu
Slide 21: Theoretical Value of Options
Theoretical Value of Options Placement Issue Offer Discount Current share price (at 14 November 2024) $0.1150 $0.400 Rights Issue offer $0.1000 Discount 13.0% Discount vs Volume Weighted Average (VWAP) Share Price (ASX) 5-day VWAP - discount 19.5% # $0.1224 $0.200 15-day VWAP - discount 11.4% # $0.1
Slide 22: Conclusion
Conclusion Overview Final stages of developing a potential “blockbuster” diagnostic product targeting a multi-$billion global market. Key Investment An attractive and comparatively simple investment proposition / business model. Highlights Transformed A business with huge potential that has gone thr
Rhythm Biosciences — Shareholder Meeting (November 2024) on 6ix